A detailed history of Jpmorgan Chase & CO transactions in Immucell Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 11 shares of ICCC stock, worth $40. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11
Previous 13 15.38%
Holding current value
$40
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$3.53 - $4.46 $7 - $8
-2 Reduced 15.38%
11 $0
Q1 2024

May 10, 2024

BUY
$4.73 - $5.47 $18 - $21
4 Added 44.44%
13 $0
Q4 2023

Feb 12, 2024

BUY
$4.45 - $5.47 $8 - $10
2 Added 28.57%
9 $0
Q3 2023

Nov 14, 2023

BUY
$4.53 - $5.61 $31 - $39
7 New
7 $0

Others Institutions Holding ICCC

About IMMUCELL CORP


  • Ticker ICCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 7,746,860
  • Market Cap $28.4M
  • Description
  • ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive ...
More about ICCC
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.